This study provides critical evidence for immunotherapy strategies in EOC, revealing the CXCL13+Th1–GC B-cell–TLS axis as a potential biomarker for predicting treatment response, offering direct guidance for the clinical design of immune checkpoint inhibitor-based combination therapies with chemotherapy.
Literature Overview
The article titled 'Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial,' published in Signal Transduction and Targeted Therapy, systematically investigates the clinical efficacy and immunomodulatory mechanisms of combining the PD-1 inhibitor tislelizumab with platinum-based chemotherapy as neoadjuvant therapy in patients with advanced epithelial ovarian cancer (EOC). Using a prospective phase II trial design, the study compares outcomes between chemotherapy alone and chemotherapy combined with immunotherapy, integrating single-cell RNA sequencing and CyTOF technology to deeply analyze dynamic changes in the tumor microenvironment (TME). Further analyses reveal associations between treatment response and specific immune cell subsets as well as tertiary lymphoid structure (TLS) activity, offering potential therapeutic targets and biomarker clues for precision immunotherapy.Background Knowledge
Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies, with approximately 70% of patients diagnosed at an advanced stage (FIGO III–IV), resulting in a 5-year overall survival rate below 45%. For patients unsuitable for primary surgery, neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) is a standard treatment option. However, multiple studies have shown that NAC does not significantly improve overall survival compared to primary debulking surgery, indicating the need for more effective therapeutic strategies. In recent years, immune checkpoint inhibitors (ICIs) have achieved breakthroughs in various solid tumors, but in unselected EOC patients, monotherapy with ICIs yields an objective response rate (ORR) of less than 15%, suggesting significant resistance mechanisms. This may be related to the immunosuppressive state of the TME, T-cell exhaustion, and lack of effective antigen presentation. Therefore, how to remodel the TME to enhance antitumor immunity has become a research hotspot. Chemotherapeutic agents such as platinum can induce immunogenic cell death, promote tumor antigen release, and upregulate MHC-I expression, theoretically enhancing the efficacy of ICIs. However, previous studies lack systematic immune profiling support. This study explores the feasibility and mechanisms of tislelizumab combined with NAC in EOC, aiming to identify key immune features predictive of response and thereby advance personalized immunotherapy strategies.
Research Methods and Experiments
The study employed a prospective, single-center, open-label, randomized controlled design (NAIVE trial, NCT04815408), enrolling 25 patients with FIGO stage IIIC–IV EOC who were randomly assigned to receive neoadjuvant chemotherapy plus tislelizumab (NACI, n=13) or chemotherapy alone (NAC, n=12). All patients received three cycles of nab-paclitaxel plus carboplatin, with the NACI group additionally receiving tislelizumab (200 mg every three weeks). The primary endpoint was 1-year progression-free survival (PFS) rate; secondary endpoints included PFS, R0 resection rate, pathological response score (CRS), and safety. High-dimensional immune profiling of tumor samples before and after treatment was performed using scRNA-seq and CyTOF, focusing on dynamic changes in T cells, B cells, macrophages, and other subsets. Monocle3 was used for pseudotime analysis to trace B-cell differentiation trajectories, and CellChat was applied to analyze intercellular communication networks. After IDS, all patients continued with adjuvant chemotherapy plus bevacizumab, and maintenance therapy was determined based on BRCA1/2 and HRD status, using PARPi ± bevacizumab or observation.Key Conclusions and Perspectives
Research Significance and Prospects
This study presents the first systematic immune dynamic map of tislelizumab combined with chemotherapy in neoadjuvant EOC treatment, revealing a strong association between TLS activity and treatment response, providing a theoretical basis for incorporating TLS as a stratification factor or predictive biomarker in future clinical trials. Moreover, the synergistic interaction between CXCL13+Th1 and GC B cells suggests that enhancing B-cell responses or promoting TLS formation could improve ICI efficacy, offering new targets for drug development, such as designing bispecific antibodies targeting CXCL13 or B-cell activation pathways.
From a clinical monitoring perspective, assessing TLS density or CXCL13+Th1 frequency in pretreatment biopsies could enable patient stratification and guide personalized treatment decisions. Additionally, the study suggests that PARPi maintenance therapy may synergize with ICIs, which requires validation in larger cohorts to optimize comprehensive management strategies for EOC.
In terms of disease modeling, this study emphasizes the need to develop patient-derived xenograft (PDX) models that preserve a complete immune microenvironment, particularly TLS structures, to more accurately simulate human EOC immune features and screen novel immunotherapies capable of activating the B-cell–T-cell–TLS axis.
Conclusion
This study provides important clinical and mechanistic evidence for immunotherapy in advanced epithelial ovarian cancer. Although tislelizumab combined with neoadjuvant chemotherapy did not significantly prolong PFS in statistical terms, its numerical advantages in 2-year PFS rate, R0 resection rate, and pathological response, combined with the 'long tail' effect revealed by immune profiling, support its potential value in specific patient populations. The key finding—that activation of the CXCL13+Th1–GC B-cell–TLS axis is closely associated with treatment response—not only offers a novel biomarker for predicting efficacy but also highlights the central role of B cells and tertiary lymphoid structures in antitumor immunity, challenging the traditional T-cell-centric paradigm of immunotherapy. This mechanistic insight directs future research toward strategies such as using combination therapies (e.g., TLR agonists, CD40 agonists) to actively induce TLS formation and thereby increase ICI response rates. From bench to bedside, this study advances the field from 'empirical combination' to 'mechanism-driven' approaches, laying the foundation for a more precise immunotherapy framework in EOC and offering hope for improving long-term outcomes in this challenging disease.
